10x Genomics has officially launched its highly anticipated Atera spatial platform during the American Association for Cancer Research (AACR) meeting in San Diego. The announcement was made at a celebratory event, marking a significant milestone for the company and the genomics community at large.
CEO Serge Saxonov emphasized that the Atera addresses a critical gap in spatial biology, offering whole-transcriptome capabilities at an unprecedented scale. With four times the throughput and significantly enhanced sensitivity compared to its predecessor, Xenium, Atera is positioned to revolutionize the analysis of complex biological systems.
The instrument, priced at $495,000, is expected to facilitate the analysis of up to 800 whole transcriptome samples annually, utilizing standard glass microscopy slides for improved compatibility in research settings. However, the introduction of Atera comes at a time when funding uncertainties may challenge researchers’ ability to invest in new technologies.
As spatial genomics continues to gain traction, particularly in oncology, the launch at AACR underscores the platform’s potential to drive forward the Human Cell Atlas initiative and enhance our understanding of cancer biology. The implications for drug development and therapeutic strategies are significant, positioning Atera as a critical tool for future research endeavors.
Get started today with Solo access →
